J
Judith W. M. Jeuken
Researcher at Radboud University Nijmegen Medical Centre
Publications - 54
Citations - 4001
Judith W. M. Jeuken is an academic researcher from Radboud University Nijmegen Medical Centre. The author has contributed to research in topics: Glioma & Comparative genomic hybridization. The author has an hindex of 30, co-authored 53 publications receiving 3745 citations. Previous affiliations of Judith W. M. Jeuken include VU University Medical Center & Radboud University Nijmegen.
Papers
More filters
Journal ArticleDOI
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Christian Hartmann,Christian Hartmann,Jochen Meyer,Jörg Balss,David Capper,Wolf Mueller,Arne Christians,Jörg Felsberg,Marietta Wolter,Christian Mawrin,Wolfgang Wick,Michael Weller,Christel Herold-Mende,Andreas Unterberg,Judith W. M. Jeuken,Peter Wesseling,Guido Reifenberger,Andreas von Deimling,Andreas von Deimling +18 more
TL;DR: An inverse association of IDH1 and IDH2 mutations of the R132C type are strongly associated with astrocytoma, while IDH 2 mutations predominantly occur in oligodendroglial tumors.
Journal ArticleDOI
Molecular diagnostics of gliomas: state of the art
TL;DR: An overview and critical appraisal of the types of genetic and epigenetic aberrations that have gained significance in the molecular diagnostics of gliomas, namely deletions of chromosome arms 1p and 19q, promoter hypermethylation of the O6-methylguanine-methyl-transferase (MGMT) gene, and the mutation status of the IDH1 and IDH2 genes are provided.
Journal ArticleDOI
MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
Martin J. van den Bent,Hendrikus J. Dubbink,Marc Sanson,Cathleen R. van der Lee-Haarloo,Monika E. Hegi,Judith W. M. Jeuken,Ahmed Ibdaih,Alba A. Brandes,Martin J B Taphoorn,Marc Frenay,Denis Lacombe,Thierry Gorlia,Winand N.M. Dinjens,Johan M. Kros +13 more
TL;DR: MGMT promoter methylation was of prognostic significance and did not have predictive significance for outcome to adjuvant PCV chemotherapy in patients with anaplastic oligodendroglial tumors (AOT).
Journal ArticleDOI
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas
Judith W. M. Jeuken,Sandra J B Cornelissen,Martine Vriezen,Marieke Dekkers,Abdellatif Errami,Angelique Sijben,Sandra H.E. Boots-Sprenger,Pieter Wesseling +7 more
TL;DR: The semiquantitative aspect of MS-MLPA may prove to be of great value, especially in predicting response to alkylating agents, not only for gliomas as evaluated in this study but also for tumors in general.
Journal ArticleDOI
The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone
Remco J. Molenaar,Dagmar Verbaan,Simona Lamba,Carlo Zanon,Judith W. M. Jeuken,Sandra H.E. Boots-Sprenger,Pieter Wesseling,Theo J. M. Hulsebos,Dirk Troost,Angela A.G. van Tilborg,Sieger Leenstra,W. Peter Vandertop,Alberto Bardelli,Cornelis J.F. Van Noorden,Fonnet E. Bleeker +14 more
TL;DR: The combination of IDH 1 mutations and MGMT methylation outperforms either IDH1 mutations or MG MT methylation alone in predicting survival of glioblastoma patients.